Viela Bio Inc

Viela Bio — Investor Presentation (January 2020)

29 slides from Viela Bio's investor presentation, Jan 10, 2020

  1. Slide 1: Corporate Presentation January 2020

    CORPORATE PRESENTATION January 2020 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risk and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financia

  3. Slide 3: Corporate Overview

    Corporate Overview Pioneering treatments for autoimmune and severe inflammatory diseases by selectively targeting critical pathways that drive disease pathogenesis Robust pipeline of novel clinical and preclinical candidates targeting three distinct pathways: autoantibody, CD40/CD40L co-stimulatory

  4. Slide 4: Strong Leadership and Strategic Partners

    Strong Leadership and Strategic Partners Bing Yao, PhD Chairman & Chief Executive Officer Mitchell Chan Chief Financial Officer Jorn Drappa, MD, PhD Chief Medical Officer, Head of R&D Bill Ragatz VP, Head of Commercial Aaron Ren, PhD VP, Head of Business Development & Operations Board of Directors P

  5. Slide 5: Robust Clinical Pipeline with Multiple Near-Term Drivers

    MOLECULE (mechanism) INDICATION DEVELOPMENT STAGE STATUS/POTENTIAL FUTURE MILESTONE GLOBAL RIGHTS PRECLINICAL PHASE 1 PHASE 2 PHASE 3 BLA Inebilizumab (Anti-CD19 mAb) Neuromyelitis Optica Spectrum Disorder 1H20: Potential BLA Approval Myasthenia Gravis Q120: Initiate Phase 2 Trial IgG4-Related Disea

  6. Slide 6: Our Clinical Approach

    Our Clinical Approach Developing precision therapies that target novel pathways in autoimmune diseases Inebilizumab Autoantibodies, secreted by a subset of B cells (plasmablasts, plasma cells), attack native tissues as opposed to foreign pathogens Autoantibody pathway VIB4920 Overstimulation of immu

  7. Slide 7: Targeting Large Market Opportunities with High Unmet Medical Needs

    Targeting Large Market Opportunities with High Unmet Medical Needs Atopic Diseases ‘Classical’ Autoimmune Diseases Barrier Function / Dysbiosis Neuroinflammatory Inflammatory Diseases SLE-Related Disease Cluster AD PP-MS MS RR-MS SP-MS B -Cell Depletion RA GM-CSFR UC a4B7 CD TNFa AS TNFa PsO IL-23 N

  8. Slide 8: Inebilizumab

    AA VIELABIO Inebilizumab

  9. Slide 9: Inebilizumab: Potential First-Line Therapy to Target & Deplete CD19-Expressing B Cells

    Inebilizumab: Potential First-Line Therapy to Target & Deplete CD19-Expressing B Cells via Autoantibody Pathway 1) Chen D, et al. J Clin Med 2016;5:107; 2) Herbst R, et al. J Pharmacol Exp Ther 2010;335:213–22; 3) Gallagher S, et al. Arthritis Rheumatol 2016;68:965–76; 4) Schiopu E, et al. Arthritis

  10. Slide 10: Neuromyelitis Optica Spectrum Disorder

    Neuromyelitis Optica Spectrum Disorder Rare and debilitating disease with unmet medical need NMOSD (previously known as Devic’s disease) is a severe and rare autoimmune disease characterized by debilitating relapse/attacks, which often leads to blindness and paralysis Data suggest that NMOSD is a B

  11. Slide 11: Inebilizumab in NMOSD

    Inebilizumab in NMOSD Largest global NMOSD trial conducted in over 99 medical centers across 24 countries Screening 28 days Randomization 3:1 N=230 Inebilizumab Day 1, Day 15 - 300mg IV Placebo Randomized Controlled Period (RCP) – 28 Weeks Open-Label Period (OLP) Primary Endpoint Time to NMO/NMOSD a

  12. Slide 12: N-MOmentum Primary Endpoint

    N-MOmentum Primary Endpoint Clinically significant reduction in risk of NMOSD attacks achieved Inebilizumab reduced risk of NMOSD attacks by 77.3% relative to placebo Inebilizumab reduced risk of NMOSD attacks by 72.8% relative to placebo CI, confidence interval; HR, hazard ratio; NNT, number needed

  13. Slide 13: N-MOmentum Results: Secondary endpoints

    N-MOmentum Results: Secondary endpoints could provide added clinical benefit * Presented p values are nominal; according to adjustments multiple comparison testing, differences considered significant if p<0·0125. 1) Proportion of participants with worsening EDSS score from baseline, with OR calculat

  14. Slide 14: N-MOmentum Open-Label Update

    N-MOmentum Open-Label Update: Data provides further validation of inebilizumb’s potential Overall Population, Randomized & Open-Label Periods Results from open-label portion of trial consistent with overall population and primary analysis 216 patients entered open-label portion of N-MOmentum trial,

  15. Slide 15: Inebilizumab: High level comparison with other treatments

    Inebilizumab: High level comparison* with other treatments approved or in development INEBILIZUMAB ECULIZUMAB SATRALIZUMAB (SA237) Mechanism-of-Action Anti-CD19 B cell deplete - targets the cells that produce pathogenic autoantibody (AQP4-IgG) (CD19+ PB/PC) as well as their precursors Anti-complemen

  16. Slide 16: Commercial Planning Strategy

    Commercial Planning Strategy Unique opportunity to focus on highest prescribers Viela has developed a dedicated commercial team for NMOSD The majority of the estimated 10K NMOSD patients are located around the top COEs and major metropolitan areas Viela has hired and trained an experienced sales tea

  17. Slide 17: Inebilizumab Life Cycle Management

    Inebilizumab Life Cycle Management Opportunity to expand into additional indications involving autoantibody pathway Kidney Transplant Desensitization Myasthenia Gravis IgG4-Related Disease Description High levels of alloantibodies in certain patients may preclude successful identification of a match

  18. Slide 18: VIB4920

    AA VIELABIO VIB4920

  19. Slide 19: VIB4920: Novel Therapy to Address Immune Overactivation

    VIB4920: Novel Therapy to Address Immune Overactivation Originating in Co-Stimulatory Pathway T cells interact with B cells, macrophages and endothelial cells through various co-stimulatory receptor-ligand interactions, including CD40/CD40L CD40L considered important component of immune responses in

  20. Slide 20: VIB4920 Overview

    VIB4920 Overview VIB4920 is a fusion protein designed to bind to CD40L on activated T cells, which is intended to prevent B cells from differentiating into plasma cells and memory cells VIB4920 also inhibits stimulation of dendritic cells and monocytes by T cells, which reduces production of pro-inf

  21. Slide 21: Phase 1b Trial Results: Reduction of autoantibodies and improved disease activity

    Phase 1b Trial Results: Reduction of autoantibodies and improved disease activity PBO VIB4920 Key Efficacy Endpoints at Day 85 N=15 75 mg N=8 500mg N=10 1,000mg N=12 1,500mg N=12 DAS-28 Adjusted Mean Change from BL (SE) (n) -1.0 (0.3) (14) 0.1(0 .4) (6) -1.2 (0.3) (10) -2.2 (0.3) (12) -2.3 (0.3) (12

  22. Slide 22: Potential to Address Multiple Indications Involving Co-Stimulatory Pathway

    Potential to Address Multiple Indications Involving Co-Stimulatory Pathway Kidney Transplant Rejection Sjögren’s Syndrome Description Current regimens to prevent transplant rejection typically include calcineurin inhibitors which often cause slow deterioration in kidney function Chronic, systemic au

  23. Slide 23: VIB7734

    AA VIELABIO VIB7734

  24. Slide 24: VIB7734: Novel Treatment Designed to Address Overactivation of Innate Immune System

    VIB7734: Novel Treatment Designed to Address Overactivation of Innate Immune System Plasmacytoid dendritic cells (pDCs) play a multifaceted role in tissue inflammation ILT7 is a cell surface molecule specific to pDCs Autoimmune diseases are associated with reduced peripheral blood pDCs with concurre

  25. Slide 25: Phase 1a SAD Data and Phase 1b MAD Design

    Phase 1a SAD Data and Phase 1b MAD Design Phase 1a Data Ongoing Phase 1b Trial Design 5 cohorts, enrolled 36 patients, 10 patients received placebo Safety Generally well-tolerated, no VIB7734-related TESAEs observed Rates and types of TEAEs reported in patients receiving VIB7734 were broadly similar

  26. Slide 26: Preclinical Candidates

    AA VIELABIO Preclinical Candidates

  27. Slide 27: Preclinical Development Plans

    Preclinical Development Plans Monoclonal antibody designed to decrease the number and function of antigen-presenting dendritic cells Preclinical toxicology study ongoing to enable IND submission Monoclonal antibody cytokine fusion protein currently in pre-clinical efficacy studies Designed to inhibi

  28. Slide 28: Upcoming Corporate Priorities

    Upcoming Corporate Priorities * This indication is one of six potential indications being studied in our ongoing Phase 1b multiple ascending dose trial, along with systemic lupus erythematous, Sjögren’s syndrome, systemic sclerosis, polymyositis and dermatomyositis. 1H2020 2H2020 Cutaneous Lupus Ery

  29. Slide 29: A VIELABIO

    A VIELABIO

Viela Bio — Investor Presentation (January 2020) on 6ix